Insider · CIK 0001727640
Lynne Marie Sullivan
Files at UBX (Unity Biotechnology, Inc.), INZY (Inozyme Pharma, Inc.), SLDB (Solid Biosciences Inc.). First filing Nov 6, 2024, latest Apr 3, 2025.
In brief
Lynne Marie Sullivan files SEC Form 4 as CFO and director at UBX (Unity Biotechnology, Inc.), and also at INZY (Inozyme Pharma, Inc.), SLDB (Solid Biosciences Inc.). Since Nov 6, 2024, Lynne Marie Sullivan has reported 0 open-market buys worth $0 and 2 open-market sells worth $23k, the latest filed on Apr 3, 2025.
A track record needs three past buys with six months of prices behind them; Lynne Marie Sullivan has 0, so none is measured yet.
The newest scored trade: sold $23k of UBX on Apr 2, 2025, filed Apr 3, 2025, scored 22 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Unity Biotechnology, Inc. | $23k 21,867 shares | -18% | - | |
| 17Weak | Unity Biotechnology, Inc. | $175 136 shares | -0% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 3, 2025 | UBX UNITY BIOTECHNOLOGY, INC. | 21,867 22.11% of outstanding | $22k | Apr 2, 2025 | $341 |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | SLDB Solid Biosciences Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +77,500 | $0.00 | $0 | 77,500 | Jun 11, 2026 |
| Jul 1, 2025 | INZY Inozyme Pharma, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,368 | - | - | 0 | Jul 3, 2025 |
| Jun 12, 2025 | SLDB Solid Biosciences Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +77,500 | $0.00 | $0 | 77,500 | Jun 13, 2025 |
| Apr 2, 2025 | UBX Unity Biotechnology, Inc. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -21,867 | $1.03 | $23k | 98,905 | Apr 3, 2025 |
| Nov 4, 2024 | UBX Unity Biotechnology, Inc. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -136 | $1.29 | $175 | 55,925 | Nov 6, 2024 |
Questions about Lynne Marie Sullivan
Answered from the filings on this page, as of the latest one.
Is Lynne Marie Sullivan buying or selling?
Not in the last 12 months. Lynne Marie Sullivan's latest open-market trade on SEC Form 4 was sold $23k of UBX on Apr 2, 2025.
How did Lynne Marie Sullivan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lynne Marie Sullivan has 0.
Where does Lynne Marie Sullivan file Form 4?
Lynne Marie Sullivan has filed Form 4 at UBX (Unity Biotechnology, Inc.) as CFO & Head of Corp. Dev.; INZY (Inozyme Pharma, Inc.); SLDB (Solid Biosciences Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.